Postoperative prophylactic lipiodolization reduces the intrahepatic recurrence of hepatocellular carcinoma.

[1]  M. Tsuneyoshi,et al.  Possible multicentric occurrence of hepatocellular carcinoma: A clinicopathological study , 1994, Hepatology.

[2]  S. Roffler,et al.  Potentiation of radioimmunotherapy by inhibition of topoisomerase I. , 1994, Cancer research.

[3]  G. Fiorentini,et al.  Hepatoma Today: Therapeutic Experiences of Multimodal Approach , 1993, Tumori.

[4]  R. Abrams,et al.  Improved survival for hepatocellular cancer with combination surgery and multimodality treatment. , 1993, Annals of surgery.

[5]  M. Makuuchi,et al.  Postresection recurrence of hepatocellular carcinoma treated by arterial embolization: Analysis of prognostic factors , 1992, Hepatology.

[6]  Y. I. Kim,et al.  [Prophylactic chemotherapy by regional arterial infusion in resected hepatoma patients]. , 1992, Gan to kagaku ryoho. Cancer & chemotherapy.

[7]  Y. Yamashita,et al.  Evaluation of oil-soluble FUdR ester for transcatheter arterial treatment of hepatomas. , 1992, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  M. Kojiro,et al.  Adenomatous hyperplasia in the vicinity of small hepatocellular carcinoma , 1992, Hepatology.

[9]  M. Morino,et al.  Primary treatment of hepatocellular carcinoma by arterial chemoembolization. , 1992, American journal of surgery.

[10]  P. Rissanen,et al.  Intra‐arterial and Intravenous Use of 4′ Epidoxorubicin Combined with 5‐Fluorouracil in Primary Hepatocellular Carcinoma: A Randomized Comparison , 1992, American journal of clinical oncology.

[11]  K. Shirabe,et al.  Factors linked to early recurrence of small hepatocellular carcinoma after hepatectomy: Univariate and multivariate analyses , 1991, Hepatology.

[12]  J. Belghiti,et al.  Intrahepatic Recurrence After Resection of Hepatocellular Carcinoma Complicating Cirrhosis , 1991, Annals of surgery.

[13]  A. Nakao,et al.  The potential role of postoperative hepatic artery chemotherapy in patients with high-risk hepatomas. , 1991, Annals of surgery.

[14]  J. Fujimoto,et al.  Prognostic factors after hepatectomy for hepatocellular carcinomas. A univariate and multivariate analysis , 1990, Cancer.

[15]  M. Shimada,et al.  Low dose 1-hexylcarbamoyl-5-fluorouracil (HCFU) recommended for cirrhotic patients with hepatocellular carcinoma. , 1989, European journal of cancer & clinical oncology.

[16]  K. Hasuo,et al.  A 5‐year experience of lipiodolization: Selective regional chemotherapy for 200 patients with hepatocellular carcinoma , 1989, Hepatology.

[17]  H. Higashi,et al.  Clinical management of recurrent hepatocellular carcinoma after primary resection , 1988, The British journal of surgery.

[18]  H. Taniguchi,et al.  Intraarterial chemotherapy with lipid contrast medium for hepatic malignancies in infants , 1987, Cancer.

[19]  M. Suenaga.  [5-Fluorouracil, tegafur, and uracil concentrations in serum and tissue of the patients with hepatocellular carcinoma after UFT administration]. , 1987, Gan to kagaku ryoho. Cancer & chemotherapy.

[20]  K. Okuda.  Early recognition of hepatocellular carcinoma , 1986, Hepatology.

[21]  S. Tashiro,et al.  Selective targeting of anti‐cancer drug and simultaneous image enhancement in solid tumors by arterially administered lipid contrast medium , 1984, Cancer.

[22]  R. Yamada,et al.  Hepatic artery embolization in 120 patients with unresectable hepatoma. , 1983, Radiology.

[23]  R. Cailleau,et al.  Mechanism of Growth Inhibition by 5-Fluorouracil. Reversal Studies with Pyrimidine Metabolites in Vitro ∗ , 1969, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[24]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[25]  N. Yamanaka,et al.  Current Status of Hepatic Resection in the Treatment of Hepatocellular Carcinoma , 1987 .